SCHEMBL405341

SCHEMBL405341

Clc1ccc2nc(Cl)nc(Cl)c2c1

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 2/20 0.44
ALDH1A1 P00352 3/20 0.43
HTT P42858 2/20 0.43
ACHE P22303 5/20 0.42
BCHE P06276 4/20 0.42
GRIN1 Q05586 4/20 0.42
GRIN2A Q12879 4/20 0.42
MAPK1 P28482 3/20 0.41
NR4A2 P43354 1/20 0.41
HPGD P15428 2/20 0.41
NPC1 O15118 1/20 0.41
RAB9A P51151 1/20 0.41
PTGES O14684 1/20 0.41
ALOX5 P09917 1/20 0.41
CYP2C9 P11712 1/20 0.41
CASP7 P55210 1/20 0.41
HIF1A Q16665 1/20 0.41
HSD17B10 Q99714 1/20 0.41
SMN1; SMN2 Q16637 2/20 0.41
MAPT P10636 2/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30013869 1.00 KDM4E (0.44) KDM4EALDH1A1HTTACHEBCHE
SCHEMBL1748521 0.83 POLB (0.50) ALDH1A1ACHEBCHEMAPK1NR4A2
SCHEMBL29909644 0.83 POLB (0.50) ALDH1A1ACHEBCHEMAPK1NR4A2
SCHEMBL17565224 0.82 HTT (0.36) KDM4EALDH1A1HTTHPGDNPC1
SCHEMBL1069650 0.79 HTT (0.41) KDM4EALDH1A1HTTHPGDSMN1; SMN2
SCHEMBL20561018 0.79 DHODH (0.42) KDM4EALDH1A1HTTACHEBCHE
SCHEMBL21877214 0.79 ESR1 (0.50) KDM4EALDH1A1HTTACHEHPGD
SCHEMBL21500731 0.79 HTT (0.68) ALDH1A1HTTACHEBCHEGRIN1
SCHEMBL8361293 0.79 ALDH1A1 (0.42) KDM4EALDH1A1HTTACHEBCHE
SCHEMBL14189290 0.79 MPO (0.57) KDM4EALDH1A1NPC1RAB9AHSD17B10

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 253 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250367188-A1 COMPOUNDS AND METHODS FOR INHIBITING NHE-MEDIATED ANTIPORT IN THE TREATMENT OF DISORDERS ASSOCIATED WITH FLUID RETENTION OR SALT OVERLOAD AND GASTROINTESTINAL TRACT DISORDERS ARDELYX, INC. (US) 2025-12-04 US disclosed
US-20250361236-A9 DIACYLGLYCEROL KINASE MODULATING COMPOUNDS GILEAD SCIENCES INC (US) 2025-11-27 US disclosed
US-20250092065-A1 2-(INDAZOL-5-YL)-6-(PIPERIDIN-4-YL)-1,7-NAPHTHYRIDINE DERIVATIVES AND RELATED COMPOUNDS AS MODULATORS FOR SPLICING NUCLEIC ACIDS AND FOR THE TREATMENT OF PROLIFERATIVE DISEASES REMIX THERAPEUTICS INC (US) 2025-03-20 US disclosed
US-20250026752-A1 POSITIVE ALLOSTERIC MODULATORS OF THE MUSCARINIC ACETYLCHOLINE RECEPTOR M4 VANDERBILT UNIVERSITY 2025-01-23 US disclosed
US-20240400568-A1 DIACYLGLYCEROL KINASE MODULATING COMPOUNDS GILEAD SCIENCES, INC. 2024-12-05 US disclosed
US-20240366590-A1 COMPOUNDS AND METHODS FOR INHIBITING NHE-MEDIATED ANTIPORT IN THE TREATMENT OF DISORDERS ASSOCIATED WITH FLUID RETENTION OR SALT OVERLOAD AND GASTROINTESTINAL TRACT DISORDERS ARDELYX, INC. 2024-11-07 US disclosed
EP-4445902-A2 DIACYLGLYCEROL KINASE MODULATING COMPOUNDS Carna Biosciences, Inc. (JP) 2024-10-16 EP disclosed
EP-4081305-B1 DIACYLGLYCEROL KINASE MODULATING COMPOUNDS CARNA BIOSCIENCES INC (JP) 2024-09-18 EP disclosed
US-12054490-B2 Diacylglycerol kinase modulating compounds GILEAD SCIENCES, INC. (US) 2024-08-06 US disclosed
CN-118324767-A Diacylglycerol kinase modulating compounds 卡尔那生物科学株式会社 2024-07-12 CN disclosed
US-5236925-A Hypotensive agents, treatment of congestive heart failure AMERICAN HOME PRODUCTS CORPORATION (US) 1993-08-17 US disclosed
WO-1993008170-A1 SUBSTITUTED HETEROCYCLES AS ANGIOTENSIN II ANTAGONISTS AMERICAN HOME PRODUCTS CORPORATION (US) 1993-04-29 WO disclosed
US-5187168-A Hypotensive agents AMERICAN HOME PRODUCTS CORPORATION (US) 1993-02-16 US disclosed
EP-0491814-A1 TETRACYCLIC IMIDAZOQUINAZOLINE DERIVATIVES, PREPARATION AND PHARMACEUTICAL COMPOSITIONS. NOVO NORDISK AS (DK) 1992-07-01 EP disclosed
WO-1991003478-A1 TETRACYCLIC IMIDAZOQUINAZOLINE DERIVATIVES, PREPARATION AND PHARMACEUTICAL COMPOSITIONS NOVO NORDISK A/S (DK) 1991-03-21 WO disclosed
EP-0417027-A1 Tetracyclic imidazoquinazoline derivatives, process for their preparation and pharmaceutical compositions containing them NOVO NORDISK A/S (DK) 1991-03-13 EP disclosed
US-4675047-A MONOCOTYLEDON WEES ICI AUSTRALIA LIMITED, 1 NICHOLSON ST., MELBOURNE, VICTORIA, 3000, AUSTRALIA, A CORP. OF AUSTRALIA 1987-06-23 US disclosed
EP-0044163-A2 Quinazolinyloxy(amino)phenoxyalkane carboxylic acid derivatives, process for their synthesis, herbicidal compositions containing them and their use as herbicides ICI AUSTRALIA LIMITED (AU) 1982-01-20 EP disclosed
US-4048312-A 2,4-Diaminoquinazolines as antithrombotic agents ELI LILLY AND COMPANY (US) 1977-09-13 US disclosed
US-3956495-A 2,4-Diaminoquinazolines as antithrombotic agents ELI LILLY AND COMPANY (US) 1976-05-11 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240400568-A1 DIACYLGLYCEROL KINASE MODULATING COMPOUNDS DGKG, DGKB, DGKK KDM4E 1748/4885ALDH1A1 4095/4885HTT 4827/4885
US-20250026752-A1 POSITIVE ALLOSTERIC MODULATORS OF THE MUSCARINIC ACETYLCHOLINE RECEPTOR M4 CHRM4, CHRM5, CHRM2 KDM4E 1325/4885ALDH1A1 3498/4885HTT 1482/4885
US-20250092065-A1 2-(INDAZOL-5-YL)-6-(PIPERIDIN-4-YL)-1,7-NAPHTHYRIDINE DERIVATIVES AND RELATED COMPOUNDS AS MODULATORS FOR SPLICING NUCLEIC ACIDS AND FOR THE TREATMENT OF PROLIFERATIVE DISEASES SNRPA, SNRPB2, HNRNPAB KDM4E 1965/4885ALDH1A1 2046/4885HTT 765/4885
US-12054490-B2 Diacylglycerol kinase modulating compounds DGKG, DGKB, DGKK KDM4E 1748/4885ALDH1A1 4095/4885HTT 4827/4885
US-20240366590-A1 COMPOUNDS AND METHODS FOR INHIBITING NHE-MEDIATED ANTIPORT IN THE TREATMENT OF DISORDERS ASSOCIATED WITH FLUID RETENTION OR SALT OVERLOAD AND GASTROINTESTINAL TRACT DISORDERS SLC10A1, SLC10A2, FABP3 KDM4E 4631/4885ALDH1A1 2512/4885HTT 1017/4885
US-20250361236-A9 DIACYLGLYCEROL KINASE MODULATING COMPOUNDS DGKG, DGKB, DGKK KDM4E 1748/4885ALDH1A1 4095/4885HTT 4827/4885
US-20250367188-A1 COMPOUNDS AND METHODS FOR INHIBITING NHE-MEDIATED ANTIPORT IN THE TREATMENT OF DISORDERS ASSOCIATED WITH FLUID RETENTION OR SALT OVERLOAD AND GASTROINTESTINAL TRACT DISORDERS SLC10A1, SLC10A2, FABP3 KDM4E 4631/4885ALDH1A1 2512/4885HTT 1017/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.